Asturias, Spain Clinical Trials

A listing of Asturias, Spain clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 53 clinical trials
featured
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

Hospital Universitario Central de Asturias /ID# 224815
 (2.4 away) Contact site
  • 164 views
  • 29 Apr, 2021
  • +224 other locations
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

durvalumab
lung carcinoma
Research Site
 (0.5 away) Contact site
  • 0 views
  • 02 Jun, 2021
  • +178 other locations
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). In Stage 1, an open-label, single-arm period, the dosing regimen will be confirmed. In Stage 2, participants will be randomized to receive either blinded ravulizumab …

Clinical Trial Site
 (0.5 away) Contact site
  • 0 views
  • 04 May, 2021
  • +43 other locations
A Study to Assess the Efficacy Safety and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.

ESP008
 (2.4 away) Contact site
  • 0 views
  • 13 Jun, 2021
  • +190 other locations
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy [gemcitabine plus cisplatin] and RC + PLND) for participants with MIBC …

Hospital Universitario Central de Asturias ( Site 0654)
 (2.4 away) Contact site
  • 0 views
  • 14 Jun, 2021
  • +32 other locations
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

The purpose of the study is to learn whether the study drug (capmatinib) helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients suffering from a particular type of lung cancer. This type of cancer is called non-small …

epidermal growth factor receptor
cancer chemotherapy
measurable disease
epidermal growth factor
growth factor
Novartis Investigative Site
 (2.4 away) Contact site
  • 0 views
  • 13 Jun, 2021
  • +42 other locations
Efficacy and Safety of Olaparib Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)

This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with Fluorouracil (5-FU) in participants with unresectable or metastatic colorectal cancer (CRC) who have not progressed following first-line induction of FOLFOX with bevacizumab. Hypothesis 1 - Olaparib + Bevacizumab is superior …

bevacizumab
colorectal adenocarcinoma
systemic chemotherapy
adenocarcinoma
folfox regimen
Hospital Universitario Central de Asturias ( Site 1153)
 (2.4 away) Contact site
  • 10 views
  • 13 Jun, 2021
  • +113 other locations
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

durvalumab
cancer chemotherapy
lung carcinoma
Research Site
 (2.4 away) Contact site
  • 102 views
  • 02 Jun, 2021
  • +241 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are that …

docetaxel
pembrolizumab
cancer
biomarker analysis
measurable disease
Hospital Central de Asturias ( Site 1002)
 (2.4 away) Contact site
  • 122 views
  • 12 Jun, 2021
  • +147 other locations
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Hospital Universitario Central de Asturias
 (2.4 away) Contact site
  • 2496 views
  • 28 Jan, 2021
  • +209 other locations